VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

Slides:

Advertisements

Similar presentations

Quality Improvement Team Members

Advertisements

Innovative Strategies for the Management of HIV Infection Dual therapies without NRTIs Jean-Guy Baril, MD Clinique médicale du Quartier Latin CHUM This.

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

IAS–USA Choosing the Initial Antiretroviral Regimen Paul A. Volberding, MD Professor of Medicine University of California San Francisco FINAL:

Management of HIV infection in HIV/HCV co-infected patients Mark Hull, MD, MHSc, FRCPC Division of AIDS University of British Columbia.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

HIV Care 2010: The 3 rd Revolution in HIV treatment Chris Farnitano, MD Noon Conference February 11, 2010.

Chicago Housing for Health Partnership: HIV Outcomes David Buchanan MD MS, Romina Kee MD MPH, Laura Sadowski MD MPH, Diana Garcia MPH North American Housing.

NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC

+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU August 27, 2014.

HIV: Acute (Primary) Infection. David H

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

VIRTUAL MEDZONE Your Resource for Hepatitis Related Innovative Medical Communication.

Efficacy of initial combination antiretroviral therapy for HIV-1: a meta-analysis Frederick J. Lee 1, Janaki Amin 2, Andrew Carr 1 Centre for Applied Medical.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

CASE 5 54 yo man HIV positive in 2001 Immune Thrombocytopenia Chronic G1a Hepatitis C Crack use daily Normotensive.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

CASE 3 43 yo man HIV+ since 2005 CD4 nadir 190 Baseline genotype…clear.

IAS–USA Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MD Professor of Medicine University of North.

CASE 4 39 yr-old man HIV Asymptomatic CD4 810 HIV viral load

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load

Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data - Heribert Knechten, MD PZB Aachen, Germany T = 5.

+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU Sept 1, 2015.

Comparison of INSTI vs INSTI  QDMRK  SPRING-2. Eron JJ, Lancet Infect Dis 2011;11: QDMRK  Design  Objective –Non inferiority of RAL QD: % HIV.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

Hit Hard, Hit Early: When to Treat and With What? Brian G. Gazzard, MD, Moderator Julio Montaner, MD Calvin J. Cohen, MD, MS.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

CASE 3 52 yo man HIV positive 1999 CD4 nadir 50 Smoker 35 pack yrs…quit 2005 COPD…chronic bronchitis Diabetic, Hypertensive, Hyperlipidemic.

Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.

Take Your HIV Medicine On Time and Every Day Educator name: Developed by: Lydia Barakat, MD, Waterbury Hospital, Waterbury, CT

Agenda  Update on Darunavir: Perry Mohammed  Update on Etravirine: Rekha Sinha  Update on TMC278: Peter Williams  Update on TMC207: Karel De Beule.

MINNESOTA’S HIV TREATMENT CASCADE April, Introduction.

Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load

CASE 2 54 yo man…HIV PCP Cryptospordiasis Chronic HepC Genotype 1a Biopsy… 2/4 activity, 3/4scarring CD4 40 No baseline genotype.

CASE 1 54 yo man HIV Generalized Anxiety/OCD VL 15,185 CD4 ranges from Baseline Genotype clear.

CASE 1 54 yo man HIV positive 8 yrs ago Tenofovir/FTC/RTV/Atazanavir x 4 yrs Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/wt.

Key HIV Research From ICAAC 2007: First-Line Antiretroviral Therapy and Switching Strategies Chicago, Illinois | September 17-20, 2007 Faculty: Cal Cohen,

CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in /2013 CD4 600 HIV viral load

Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients G Fätkenheuer 1 ; S Staszewski 2 ; A Plettenburg 3 ;

HIV Part Dos By Alaina Darby.

HIV Tutoring By Alaina Darby.

Take Your HIV Medicine On Time and Every Day

Maia Pinsky, MD-R3 Family Medicine Residency of Idaho

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

David Fletcher MD FRCPC Benny Chang MD CCFP Fred Crouzat MD CCFP

CASE 2 53 yo man HIV CD4 340/16% (Nadir) VL 30,100 c/ml.

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Reduced Costs Service & Support Innovative Technology Performance Quality.

Reduced Costs Service & Support Innovative Technology Performance Quality.

دانشگاه علوم پزشکی بوشهر برنامه ملی مبارزه با بیماریهای واگیر

HIV در مادران و کودکان.

مبارزه با بیماریها دکتر آناهیتا بابک. مبارزه با بیماریها دکتر آناهیتا بابک.

Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.

Epidemic of Lung Cancer in Patients With HIV Infection

Қош келдіңіздер.

Best Practices for Patients With Chronic Migraine

Comparison of NRTI combinations

UTMB/CMC MEDICALLY FOCUSED HIV DISCHARGE PLANNING

Hepatitis C Genotypes: Current Trends and Future Implications

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Comparison of NRTI combinations

Comparison of NRTI combinations

Comparison of NNRTI vs NNRTI

Presentation transcript:

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication

HIV CASE PRESENTATIONS Anita Rachlis MD FRCPC Ken Logue MD David Fletcher MD FRCPC

CASE 1 49 yo man HIV CD4 400 Asymptomatic

CASE 1 DATEREGIMENCD4VL 1996AZT/3TC/INDINAVIR120? D4T/3TC/RTV/SQV200/10%13,

CASE 1 DATEREGIMENCD4VL D4T/3TC/ RTV/SQV 200/10% ABC/DDI/ RTV/LPV/NVP /14%

CASE 1 GENOTYPE MAR/03

CASE 1 DATEREGIMENCD4VL ABC/DDI/ RTV/LPV/NVP /14% ABC/DDI/RTV/ LPV/APV/ NVP/T /16%< ABC/3TC/RTV/ DRV/RGV/NVP (bid) /18%<50

CASE 1 APRIL 2011 Patient informs physician of OD pill taking for the last year despite a bid script!!!! ABC/3TC/ ½ dose RTV/DRV/RGV/NVP Despite this…HIV Viral Load<39!!! WHAT WOULD YOU DO?

CASE 1 GENOTYPE MAR/03

CASE 1 OD ABC/3TC/RTV 100mg/DRV 1200mg/RGV 800 mg/ETV 400mg ?Role Of OD DRV ?Role of Etravirine ?Role of TDF/FTC ?Role of Maraviroc

CASE 1 49 yo man HIV CD4 400 Asymptomatic

CASE 1 49 yo man HIV CD4 400 Asymptomatic

CASE 1 49 yo man HIV CD4 400 Asymptomatic